07 Mar 2017
Abzena inside product progresses to Phase II
Abzena has announced the progression of one of the Abzena inside Composite Human Antibody products into a Phase II clinical trial. The product is being developed by a major US pharmaceutical company for the treatment of neurodegenerative conditions. We have increased our valuation to £105m (vs £102m) as a result of an increase of the Abzena inside product’s assigned probability (to 35% from 15%).
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Abzena inside product progresses to Phase II
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
07 Mar 2017 -
Author:
Dr Linda Pomeroy -
Pages:
3
Abzena has announced the progression of one of the Abzena inside Composite Human Antibody products into a Phase II clinical trial. The product is being developed by a major US pharmaceutical company for the treatment of neurodegenerative conditions. We have increased our valuation to £105m (vs £102m) as a result of an increase of the Abzena inside product’s assigned probability (to 35% from 15%).